Key financial ranges
Market cap · USD equivalent
P/E ratio
Annual revenue · USD equivalent
Revenue growth
Valuation & profitability
Price / sales
Annual net income · USD equivalent
Net profit margin
Cash & debt
Cash · USD equivalent
Total debt · USD equivalent
Net cash · USD equivalent
Debt / revenue
| Company | Market cap | P/E | Revenue | Rev. growth | Net income | Cash | Debt | AI value |
|---|---|---|---|---|---|---|---|---|
| CALMCal-Maine Foods Inc | $3.52B | 11.4× | $2.91B | -31.7% | $316.68M | $107.22M | $1.44M | Fair valued |
| NHINational Health Investors Inc | $3.52B | 20.7× | $80.06M | +47.1% | $142.18M | $30.39M | $1.28B | Fair valued |
| GPIGroup 1 Automotive Inc | $3.52B | 12.3× | $22.57B | +13.2% | $325.2M | $164.5M | $3.61B | Fair valued |
| KAIKadant Inc | $3.53B | 32.1× | $1.05B | -0.1% | $101.97M | $134.53M | $510.63M | Fair valued |
| AWRAmerican States Water Co | $3.53B | 24.4× | $136.74M | +8.2% | $130.44M | $21.66M | $725.27M | Overvalued |
| PTRNPattern Group Inc. | $3.54B | — | $2.5B | +39.3% | $16.25M | $345.83M | $51.31M | Fair valued |
| BTUPeabody Energy Corp | $3.54B | — | $3.86B | -8.9% | -$42.5M | $526.3M | $424.9M | Fair valued |
| GRALGRAIL, Inc. | $3.55B | — | $147.17M | +17.2% | -$408.35M | $55.65M | $91.31M | Overvalued |
| DNLIDenali Therapeutics Inc. | $3.55B | — | $0 | — | -$512.54M | $201.53M | $37.69M | Fair valued |
| WSCWillScot Holdings Corp | $3.56B | — | $2.28B | -4.8% | -$52.99M | $18.17M | $3.79B | Undervalued |
| PIIPolaris Inc. | $3.56B | — | $7.15B | -0.3% | -$465.5M | $282M | $2.21B | Fair valued |
| LIFLife360, Inc. | $3.57B | 25.6× | $489.48M | +31.8% | $150.83M | $267.06M | $311.64M | Overvalued |
| HNIHni Corp | $3.57B | 449.3× | $2.84B | +12.4% | $54.2M | $105M | $1.64B | Undervalued |
| LXPLXP Industrial Trust | $3.58B | 61.3× | $4.09M | -0.4% | $113.16M | $130.11M | $1.36B | Fair valued |
| FLYFirefly Aerospace Inc. | $3.6B | — | $159.86M | +163.0% | -$298.34M | $459.82M | $33.81M | Overvalued |
| PLMRPalomar Holdings, Inc. | $3.6B | 18.4× | $875.97M | +58.2% | $197.07M | $62.69M | $295.77M | Undervalued |
| TRMDTORM plc | $3.6B | 6.0× | $1.34B | -14.1% | $286M | $158.1M | $1.16B | Fair valued |
| BDRXBiodexa Pharmaceuticals Plc | $3.61B | — | £381K | -45.5% | -£7.08M | £8.53M | £61K | Undervalued |
| MANUManchester United plc | $3.61B | — | £666.51M | +0.7% | -£33.02M | £44.41M | £780.4M | Overvalued |
| KENKenon Holdings Ltd. | $3.61B | 44.5× | $871.93M | +16.1% | $148.26M | $1.48B | $1.78B | Fair valued |